Revenue

12 Months Ended

Sep. 30, 2022

Revenue From Contract With Customer [Abstract]

Revenue

3. Revenue

The following is a disaggregation of revenue within each reportable segment:

	Fiscal Year
(In thousands)	2022		2021		2020
Medical Device
Product sales	$	27,930	$	21,777	$	21,608
Royalties		30,267		30,781		28,614
License fees		5,981		16,275		12,020
Research, development and other		8,211		9,420		9,159
Medical Device revenue		72,389		78,253		71,401
In Vitro Diagnostics
Product sales		26,691		24,701		22,709
Research, development and other		871		2,182		754
In Vitro Diagnostics revenue		27,562		26,883		23,463
Total Revenue	$	99,951	$	105,136	$	94,864

Contract assets totaled $7.1 million as of each of September 30, 2022 and 2021 on the consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 4 Collaborative Arrangement.

Revenue from customers that equaled or exceeded 10% of total revenue was as follows:

	Fiscal Year
	2022			2021			2020
Abbott		11	%		21	%		19	%
Medtronic		13	%		13	%		14	%